What is New Lantern?
New Lantern operates at the intersection of artificial intelligence and clinical diagnostics, providing a sophisticated suite of cloud-native PACS solutions. By deploying tools such as Smart Worklist, PACS Viewer, and AI Reporter, the company addresses the critical need for efficiency in radiology departments. Their platform is engineered to automate labor-intensive reporting tasks, thereby enhancing diagnostic precision and reducing the administrative burden on healthcare providers. As a specialized player in the health-tech ecosystem, New Lantern distinguishes itself through a commitment to cost-effective, scalable infrastructure that supports high-volume diagnostic environments.
How much funding has New Lantern raised?
New Lantern has raised a total of $19M across 1 funding round:
Series A
$19M
Series A (2024): $19M with participation from Benchmark
Key Investors in New Lantern
Benchmark
Benchmark is a prominent venture capital firm based in San Francisco, recognized for its early-stage backing of transformative technology companies and its history of high-impact strategic investments.
What's next for New Lantern?
With the recent influx of capital, New Lantern is poised to transition from its current scaling phase into broader market penetration. The strategic roadmap likely involves deepening the integration of its AI-driven diagnostic tools and expanding its footprint within large-scale healthcare institutions. By leveraging this investment, the company aims to solidify its competitive advantage, focusing on product innovation that drives diagnostic confidence and operational throughput. Future efforts will likely prioritize the refinement of its cloud-native architecture to meet the evolving demands of global radiology practices, ensuring that the firm remains a cornerstone of modern medical imaging infrastructure.
See full New Lantern company page
